Search results
Psoriasis: Features That May Affect Biologic Rx Outcomes
Medscape· 5 days agoSeveral clinical characteristics were negatively associated with responses to biologics in a...
FDA Approves Skyrizi for Ulcerative Colitis
Medscape· 4 days agoThe approval is the fourth indication for the anti–interleukin 23 monoclonal antibody after approval for Crohn's disease, psoriatic arthritis, and plaque...
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks via Yahoo Finance· 2 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 15 hours agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
American Trust Takes Position in Amgen Inc. (NASDAQ:AMGN)
ETF DAILY NEWS· 7 days agoAmerican Trust acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and ...
AbbVie (NYSE:ABBV) Given New $190.00 Price Target at Piper Sandler
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Get Free Report) had its price objective boosted by research analysts at Piper Sandler from $185.00 to $190.00 in a research note issued on Tuesday, Benzinga reports. Piper ...
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 3 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
JD Supra: AbbVie Files Notice of Data Breach Impacting the Health Information of Tens of Thousands...
JD Supra· 11 hours agoOn May 22, 2024, AbbVie, Inc. filed a notice of data breach with the Attorney General of Texas after discovering that confidential information that had been entrusted to the company was subject ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 2 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
In a 'gold rush' for treating bowel disease, AbbVie clears one more stage
Crain s Chicago Business· 3 days agoWith the arrival of biosimilar competition for its blockbuster drug Humira, AbbVie has said much of its sales growth potential lies with these two anti-inflammatories. In April, the North Chicago ...